Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, open-label study to evaluate the safety and efficacy of a consecutive treatment regimen of clobetasol propionate 0.05 percent spray, followed by calcitriol ointment 3microg/g, in the management of moderate to severe plaque psoriasis

Next Previous
Trial Profile

A multi-center, open-label study to evaluate the safety and efficacy of a consecutive treatment regimen of clobetasol propionate 0.05 percent spray, followed by calcitriol ointment 3microg/g, in the management of moderate to severe plaque psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Calcitriol (Primary) ; Clobetasol (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Galderma

Most Recent Events

  • 01 Sep 2009 Status changed from active, no longer recruiting to completed.
  • 22 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
  • 05 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top